Last reviewed · How we verify
NCT05830019
Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
NA trial testing carbon ion radiotherapy in Pancreatic Carcinoma in 49 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Shanghai Proton and Heavy Ion Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 1 June 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- carbon ion radiotherapy
Conditions studied
- Pancreatic Carcinoma — all drugs for Pancreatic Carcinoma →
Sponsor
Shanghai Proton and Heavy Ion Center — full company profile →
Who can join
Adults 18 to 80, any sex, with Pancreatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05830019
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of carbon ion radiotherapy
Trials testing the same drug.
- NCT06311981 — Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients · Phase 2 · recruiting
- NCT06186726 — Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors · Phase 2 · recruiting
- NCT04724577 — 12 Fractions Carbon Ion Radiotherapy for Localized Prostate Cancer · NA · unknown
- NCT04082455 — Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer · NA · unknown
Other recruiting trials for Pancreatic Carcinoma
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT06995898 — The Vanguard Study: Testing a New Way to Screen for Cancer · NA · recruiting
- NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting
Other Shanghai Proton and Heavy Ion Center trials
Trials by the same sponsor.
- NCT07135661 — Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy · NA · recruiting
- NCT05613452 — Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT06677879 — A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. · Phase 2 · recruiting
- NCT05878678 — Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position · Phase 2 · unknown
- NCT05692661 — A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05830019 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Proton and Heavy Ion Center
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05830019.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing